Suggested remit: To appraise the clinical and cost effectiveness of epcoritamab with rituximab and lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6586
Provisional Schedule
- Committee meeting: 1:
- 08 September 2026
- Expected publication:
- 28 October 2026
Project Team
- Project lead
- Leena Issa
Email enquiries
If you have any queries please email TACommC@nice.org.uk
Stakeholders
- Companies sponsors
- AbbVie (epcoritamab)
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Lymphoma Action
- Professional groups
- Association of Cancer Physicians
- Cancer Research UK
- Royal College of Pathologists
- Royal College of Physicians
- Royal College of Radiologists
- Associated public health groups
- None
- Comparator companies
- Incyte Biosciences UK (tafasitamab) (confidentiality agreement signed, participating)
- AbbVie (epcoritamab) (confidentiality agreement not signed, not participating)
- Amarox (lenalidomide) (confidentiality agreement not signed, not participating)
- Biocon Pharma (lenalidomide) (confidentiality agreement not signed, not participating)
- Bristol Myers Squibb (lenalidomide) (confidentiality agreement not signed, not participating)
- Celltrion Healthcare (rituximab) (confidentiality agreement not signed, not participating)
- Dr Reddy’s Laboratories (bendamustine, rituximab) (confidentiality agreement not signed, not participating)
- Grindeks Kalceks UK (lenalidomide) (confidentiality agreement not signed, not participating)
- Mylan (lenalidomide) (confidentiality agreement not signed, not participating)
- Pfizer (rituximab) (confidentiality agreement not signed, not participating)
- Roche (obinutuzumab, rituximab) (confidentiality agreement not signed, not participating)
- Sandoz (lenalidomide, rituximab) (confidentiality agreement not signed, not participating)
- Seacross Pharmaceuticals (bendamustine) (confidentiality agreement not signed, not participating)
- Sun Pharma (lenalidomide) (confidentiality agreement not signed, not participating)
- Teva UK (lenalidomide) (confidentiality agreement not signed, not participating)
- Thornton & Ross (lenalidomide) (confidentiality agreement not signed, not participating)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 15 April 2026 | This appraisal has been delayed and will now be considered by the NICE Technology Appraisal Committee at a meeting on Tuesday 8 September 2026. - Note added to the project documents |
| 24 November 2025 | Invitation to participate |
| 17 September 2025 - 15 October 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 02 October 2025 | To appraise the clinical and cost effectiveness of Rituximab + Lenalidomide + Epcoritamab within its marketing authorisation for treating follicular lymphoma - Note added to the project documents |
| 17 September 2025 | In progress. Scoping commenced. |
| 15 May 2025 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual